Ting Zhao, MD

🚨💡Excited to share our new publication @Histo_Journal Clinicopathologic, immunohistochemical and genomic characterization of urothelial carcinoma with myxoid and chordoid features @BWHPath @MGHPathology @MGBpathology doi.org/10.1111/his.15… #GUpath #Molpath 🧬

Great question! FOXA1 Y243F has been reported to be associated with a higher Gleason score (PMID: 37351993). In contrast, although C-terminal truncating FOXA1 mutations have been associated with castration resistance and poor clinical outcomes in prostate cancer, their direct association with a higher Gleason score has not been clearly established.

@TingZhaoPathdoc @MGBpathology Nice example, thank you! Curious, are these FOXA1 truncating variants usually associated with higher Gleason Grade Groups or a specific histologic pattern?

What is the clinical significance of detecting the truncating FOXA1 p.His398LeufsTer17 variant in metastatic prostatic adenocarcinoma? #PathTwitter #MolPath #GUpath @MGBpathology

AR p.Thr878Ala (T878A) also mediates castration resistance in prostate cancer #MolPath #GUpath x.com/TingZhaoPathdo…

💠FOXA1 C-terminal truncation mutations are linked to castration resistance and poor outcome in prostate cancer 💠HNF_C domain mediates transcriptional activation #MolPath #GUpath

Great question! Yes, AR is still expressed in most castration-resistant prostate cancer, but a substantial subset becomes AR-low/negative. AR expression/signaling is sustained by several recurring mechanisms, including AR amplification/overexpression, splice variants, activating point mutations, altered androgen synthesis, and cofactor changes. (PMID: 30209899; 27799360)

@TingZhaoPathdoc @MGBpathology I have a question, is AR still going to expressed in the drug resistant pc?

What is the clinical significance of detecting AR p.Thr878Ala (c.2632A>G) in metastatic prostatic adenocarcinoma? #PathTwitter #MolPath #GUpath @MGBpathology

@kriyer68 👍🎯

@TingZhaoPathdoc @drkennethtang @MGBpathology Acquired drug resistance and tumor evolution.

💠AR p.Thr878Ala (T878A) is a ligand-binding domain (LBD) mutation of the androgen receptor 💠AR T878A can emerge or be selected during abiraterone therapy (an androgen synthesis inhibitor), with a significantly higher post-treatment prevalence, supporting its role in acquired resistance #Molpath #GUpath

💠Patients with androgen receptor (AR) ligand-binding domain (LBD) mutations have worse overall survival than those without LBD mutations 💠Patients harboring AR p.Thr878Ala (T878A) also have worse overall survival than those without the mutation #MolPath #GUpath

AR p.Thr878Ala (T878A) mediates castration resistance in prostate cancer #MolPath #GUpath 💠Broadens AR ligand specificity (allowing activation by noncanonical steroids, such as progesterone, and some antiandrogens) 💠Alters coactivator recruitment → enhanced AR signaling

@byrk_bsr Congrats, Dr. Bayrak!!🎉👍

Every publication tells a story. A story of curiosity, collaboration, perseverance, and the lifelong pursuit of wisdom. Looking back, I feel far more grateful than proud. The journey continues. 🤍 #GUPath #Pathology #Research #AcademicMedicine

@ariella8 Thank you so much for your support, Dr. Stayerman! It is truly an honor. I really appreciate your encouragement!🙏😊

#PathTweetAward #PathTweetAward2026 Congratulations, @TingZhaoPathdoc , on being selected as the Top Tweet in the Trainee category for June! Your consistently outstanding educational posts and valuable contributions continue to enrich the #PathX community.👏👏👏👏👏

@patholojenMD Thank you very much, Jenn! Hope you're enjoying your fellowship :)

@TingZhaoPathdoc @smlungpathguy @MGBpathology @PathTweetAward @PoojaSMD @ahsanuitis @VHNguyenMD Many congrats Ting this is awesome!

🏆🎉I'm honored to be the winner of the June #PathTweetAward in the Trainee category. Thank you to the organizers and everyone in the pathology community for your support and encouragement! 🙏 #Molpath #GUpath @MGBpathology @PathTweetAward @PoojaSMD @ahsanuitis @VHNguyenMD @AmyHDeekenMD

@Janiranavarro Thank you very much, Janira! I've learned a lot from your posts👍

@TingZhaoPathdoc @MGBpathology @PathTweetAward @PoojaSMD @ahsanuitis @VHNguyenMD Congratulations Ting! Your posts are amazing! ✨🎉

@MirunaPopescu13 Thank you very much, Miruna! 😊🙏

@TingZhaoPathdoc @MGBpathology @PathTweetAward @PoojaSMD @ahsanuitis @VHNguyenMD Congrats!!

@smlungpathguy Thank you very much, Dr. Mukhopadhyay! It's an honor to be part of the global pathology community 🙏

@TingZhaoPathdoc @MGBpathology @PathTweetAward @PoojaSMD @ahsanuitis @VHNguyenMD #PathTweetAward was established with this in mind: encourage all the good teachers in pathology no matter where they post from in the world. Congrats!

@ahsanuitis Thank you very much, Dr. Gill! I'll keep up the good work 😊

@TingZhaoPathdoc @MGBpathology @PathTweetAward @PoojaSMD @VHNguyenMD Congratulations @TingZhaoPathdoc ! Very well deserved. Keep up the great work! 👏👏

We’re proud to launch CAPA Grand Rounds with an inaugural lecture by Dr. Syed Z. Ali from @JHUPath. Join us on Aug 13 (Thu), 12 PM ET, for “The Bethesda Thyroid Revolution: Impact, Challenges, and Future Directions.” Don’t miss this timely update on thyroid #CytoPath #PathTwitter

@patxiqueipo Great thought! Although Paneth-like cells have been reported in acquired cystic disease-associated and clear cell RCCs (PMID: 33516060), the tumor cells in the current tumor does not appear to show similar features.

@TingZhaoPathdoc @ariella8 One question,could be possible that some clear cells look with Paneth like granules?

#GUPath #NewOnPath Congratulations on this @TingZhaoPathdoc